News

Gland Pharma Limited announced the appointment of Mr. Deepak Sapra as the new Chief Executive Officer (CEO), subject to his acceptance of the offer, with an effective date of November 16, 2026. Mr. Sapra, who currently serves as Chief Executive Officer – API and Services at Dr. Reddy’s Laboratories Limited and a Board Member of Aurigene Pharma Services, brings 27 years of executive experience, including over 23 years in the pharmaceutical industry.

Net profit of Gland Pharma rose 47.09% to Rs 316.96 crore in the quarter ended June 2026 as against Rs 215.48 crore during the previous quarter ended June 2025. Sales rose 19.57% to Rs 1800.27 crore in the quarter ended June 2026 as against Rs 1505.62 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales1800.271505.62 20 OPM %27.1824.43 - PBDT546.23413.79 32 PBT434.98312.74 39 NP316.96215.48 47 Powered by Capital Market - Live News

Gland Pharma and Neuland Laboratories today announced a long-term strategic CDMO partnership. Under the partnership Gland will establish a sterile manufacturing suite for Active Pharmaceutical Ingredients (APIs) pertaining to microparticle depot products. The collaboration combines Neuland`s Complex API development and manufacturing capabilities including deep expertise in complex chemistry, process development, custom manufacturing having a strong track record of serving global innovator and generic pharmaceutical companies; with Gland Pharma`s global sterile manufacturing expertise and strong regulatory compliance track record, to serve growing worldwide demand for sterile APIs used in microparticle depot products and other complex sterile APIs. Under the collaboration, Gland Pharma will expand its existing sterile manufacturing infrastructure through an additional dedicated suite at its JNPC facility at Visakhapatnam to support Neuland for its growing demand of sterile APIs. The facility will be constructed and operated to cGMP, USFDA and EU standards, and will be backed by Gland Pharma`s proven aseptic manufacturing expertise. Together, the companies will offer an integrated CDMO solution encompassing development, scale-up, regulatory support and commercial manufacturing of sterile APIs. The suite will be designed to add approximately 1400 kg of annual capacity, providing manufacturing flexibility across multiple sterile products while supporting future growth.

Gland Pharma (Gland or Company), a generic injectable & ophthalmic focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), BRIDION� Injection of Merck Sharp & Dohme LLC. The Product is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.

Gland Pharma will hold a meeting of the Board of Directors of the Company on 10 August 2026.